SCHEMBL78562

SCHEMBL78562

CCC(CC)(c1ccc([N+](=O)[O-])cc1)P(=O)(O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
POLB P06746 1/20 0.51
AKR1C3 P42330 1/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 2/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
PTPRC P08575 1/20 0.44
ACHE P22303 2/20 0.43
BCHE P06276 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
MAPT P10636 3/20 0.42
CA12 O43570 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP14 P50281 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7870277 0.84 PGK1 (0.44) ALDH1A1
SCHEMBL2033791 0.81 ALDH1A1 (0.47) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL2037217 0.81 PTPRC (0.65) ALDH1A1CA1CES2CES1PTPRC
SCHEMBL9798929 0.80 CYP3A4 (0.42) ALDH1A1POLBPTPRCMAPTMAPK1
SCHEMBL3434696 0.80 ALDH1A1 (0.42) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL2032900 0.78 ALDH1A1 (0.50) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL5859053 0.78 PTPN5 (0.46)
SCHEMBL3230183 0.77 PTPRC (0.51) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL2637314 0.77 PTPRC (0.51) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL8061160 0.77 GPR35 (0.45) ALDH1A1POLBPTPRCMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025262152-A1 CONDUCTIVE POLYMER DISPERSIONS FOR IMPROVED STABILITY PERFORMANCE OF CAPACITORS HERAEUS EPURIO GMBH (DE) 2025-12-26 WO disclosed
EP-4668303-A1 CONDUCTIVE POLYMER DISPERSIONS FOR IMPROVED STABILITY PERFORMANCE OF CAPACITORS Heraeus Epurio GmbH (DE) 2025-12-24 EP disclosed
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS LILLY CO ELI (US) 2025-11-20 US disclosed
US-20250099494-A1 PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2025-03-27 US disclosed
EP-4467552-A1 PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF Haihe Biopharma Co., Ltd. (CN) 2024-11-27 EP disclosed
WO-2023138637-A1 PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF 上海海和药物研究开发股份有限公司 2023-07-27 WO disclosed
US-11242554-B2 Nitrodiarylethenes as fluorescence quenchers for nucleic acid probes ELITECHGROUP, INC. (US) 2022-02-08 US disclosed
EP-2363392-B1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES UNIV PENNSYLVANIA (US) 2017-05-03 EP disclosed
EP-2437792-B1 IMAGING OF MYELIN BASIC PROTEIN GEN ELECTRIC (US) 2015-10-21 EP disclosed
US-8840866-B2 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-09-23 US disclosed
WO-2009158516-A1 SCHWEINFURTHIN ANALOGUES UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2009-12-30 WO disclosed
US-20090123369-A1 Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2009-05-14 US disclosed
EP-1999109-A2 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES The Trustees Of The University Of Pennsylvania (US) 2008-12-10 EP disclosed
US-20080248053-A1 Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases SEATTLE GENETICS, INC. (US) 2008-10-09 US disclosed
EP-1910290-A2 GPCR AGONISTS Prosidion Limited (GB) 2008-04-16 EP disclosed
US-20080038195-A1 radiolabeling; neurodegenerative diseases THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2008-02-14 US disclosed
WO-2007126733-A2 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2007-11-08 WO disclosed
WO-2007003962-A2 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed
US-20060182751-A1 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use GENENTECH, INC. (US) 2006-08-17 US disclosed
US-20050238649-A1 Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases SEATTLE GENETICS, INC. (US) 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080248053-A1 Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases MMAB, CAD, VIM ALDH1A1 3798/4885POLB 4455/4885AKR1C3 2298/4885
US-20060182751-A1 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use CCNY, CCNI, MKI67 ALDH1A1 935/4885POLB 502/4885AKR1C3 856/4885
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R ALDH1A1 3227/4885POLB 4322/4885AKR1C3 26/4885
US-11242554-B2 Nitrodiarylethenes as fluorescence quenchers for nucleic acid probes DNTT, NME2, DUT ALDH1A1 640/4885POLB 399/4885AKR1C3 628/4885
US-20050238649-A1 Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases CAD, MMAB, AURKC ALDH1A1 4361/4885POLB 3987/4885AKR1C3 2346/4885
US-20250099494-A1 PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF ENPP1, ENPP3, PPA1 ALDH1A1 1602/4885POLB 2608/4885AKR1C3 905/4885
US-20080038195-A1 radiolabeling; neurodegenerative diseases APP, PSEN1, HTT ALDH1A1 2974/4885POLB 3351/4885AKR1C3 2997/4885
US-20090123369-A1 Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques APP, APBA1, PSEN1 ALDH1A1 3305/4885POLB 4372/4885AKR1C3 3884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.